Senior Pathologist, Biomarker Scientist

Qin Su, MD, PhD

Email: *****@*****.***. Tel: 617-***-****. Residence: Boston area, MA

Expertise areas:

Anatomical pathology and molecular pathology, board-certified.

Molecular diagnostics and Immunoassays, including immunohistochemistry (IHC), in situ

hybridization (ISH), image analysis, Western blotting, PCR, RT-PCR, CGH, sequencing- based

genetic/genomic analysis and expression profiling, ELISA and flow cytometry.

Biomarker discovery/validation; in vitro diagnostics (IVD) and companion diagnostics

(CDx); assay development/validation/transfer and result evaluation (scoring algorithms).

Project design and management with multi-task implementation capacities; laboratory

management with Quality Systems (GLP/GCP/CAP); tumor and reference tissue bank.

Leadership with cross-functional communication/coordination skills, excellent presentation and

organizational abilities and experience in collaborations with external partner laboratories.

Oncology, immuno-oncology, immunology and virology researches, particularly on Liver,

GI, lung, breast, prostate cancers, melanoma, lymphomas and lymphoid tissue sarcomas.

Translational medicine and translational research sciences for personalized healthcare.

Animal models for oncology, virology, tissue injury/ fibrosis and metabolic diseases.

Summary of education and professional experiences:

Qin Su was a Senior Clinical Pathologist in Roche Pathology and Tissue Analytics (PTA) at Roche

R&D Center China from October 2011 to May 2014, and also served as Head of Tissue Biomarker

and Pathology Lab, Roche Translational Research Sciences (TRS) during the period, providing

supports to clinical and preclinical studies with his expertise in pathology and Biomarker Assays.

He got his Bachelor in Medicine (equivalent to MD in the US), Master (Immunopathology) and PhD

(Molecular Pathology) in China. He has served as a board-certified pathologist for >20 years prior to

joining Roche. He was a professor and PhD fellow supervisor and headed Pathology Departments

in two top university hospitals in China from 1995 to 2011. He worked in German Cancer Research

Center as a guest scientist for >3 years. He has published >30 papers in peer review international

journals, more than 100 journal articles in Chinese periodicals, and contributed 9 book chapters.

Work experiences and selected achievements:

2011/09-2014/05: Senior Clinical Pathologist, Head of Tissue Biomarker & Pathology Lab, Roche

Translational Research Sciences (TRS) at Roche R&D Center, Shanghai.

Supported several clinical studies with target validation and PD/predicative biomarker assays

on pulmonary, gastric, nasopharyngeal and hepatocellular carcinomas and HBV infection.

Development of IHC and ISH platforms for macrophage polarization, dendritic cells and

effector immune cells for cancer immunology studies.

Supported drug discovery studies in own labs and with external partners with target/biomarker

discovery/validation and tissue analysis for 12 oncologic and virology projects.

Supported translational medicine with biomarker strategies and translational researches.

Two Major Milestone Awards obtained for the contributions to the TLR7 APAC Project and to

an HBV Project. Roche pRED Shanghai, 2014.

2003/05-2011/09: Chinese Academy of Medical Sciences Cancer Hospital, Beijing. Professor, PhD

fellow advisor, Vice Chairman, Department of Pathology.

Diagnostic works and establishment/management of Laboratory of Molecular Pathology with

IHC, ISH, CGH, PCR- and sequencing-based genetic/genomic analysis.

Described sequential processes of preneoplastic and premalignant lesions in human liver and

their progression to hepatocellular carcinoma by morphologic and genetic assays.

1

Molecular diagnostics and translational studies for diagnostic, prognostic and therapeutic

biomarkers based on tissue and blood samples mainly in the fields of oncology and virology.

Participated in several clinical studies (Phases 2 and 3) with biomarker strategies, assay

result and pathologic validation as the Director of the Reference Pathology Lab.

Executed biweekly multidisciplinary meetings and related collaborations as the Vice

Chairman of the Center for Diagnosis and Treatment of Lymphomas.

1995/09-2003/09: Fourth Military Medical University Tangdu Hospital, Xi’an. Professor, Chairman,

Department of pathology, PhD Fellow Advisor.

Diagnostic works as a Consultation Pathologist, as well as administration works.

Establishment/management of Immunohistochemistry Lab and Molecular Pathology Lab.

Identification of preneoplastic and premalignant lesions in human liver with various disorders.

Demonstration of abnormal cytokeratin expression in liver and its association to laminin.

1999/07-2000/08: German Cancer Research Center, Heidelberg. Guest Scientist.

Establishment of an RT-PCR-based assay for different HBV transcripts.

1996/01-1998/01: German Cancer Research Center, Guest Scientist.

Described sequential processes of preneoplastic and premalignant lesions in human livers.

Development of an HBx assay, demonstration of expression in hepatocellular carcinoma and

its precursors in HBV-infected liver, and its relationship with p53 protein.

1990/09-1995/09: Fourth Military Medical University Tangdu Hospital, Xi’an. Vice Professor, Vice

Chairman (since 1992), Department of pathology.

Education:

1987/09-1990/09: PhD, Fourth Military Medical University, Molecular Pathology.

1983/02-1986/02: Master of Medicine, Fourth Military Medical University, Immunopathology.

1978/02-1982/02: Bachelor of Medicine, Weifang Medical College (equivalent to MD in the US).

Selected grants (as the principal investigator):

National Natural Science Foundation of China (NSFC; No. 3880376): Detection of insulin-like

growth factor II in chronic hepatitis B, cirrhosis and hepatocellular carcinoma. 1989-1992.

NSFC (No. 39470778): Identification and characterization of a type of small epithelial cells in

liver tissues with chronic hepatitis B or cirrhosis. 1992-1995.

NSFC (No. 30171052): Clonality of precancerous nodules and foci in human liver. 2002-2005.

NSFC (No. 30572125): Genetic alterations in precancerous nodules from human liver. 2006.

NSFC (No. 30772508): Detection of X-chromosomal inactivation skewing in female blood

cells and its value in cancer susceptibility assessment. 2008.

Selected journal publications (* as correspondent or first author):

1. Li G, Jin T, Liang H, Tu Y, Zhang W, Gong L, Su Q*, Gao G. Skewed X-chromosome inactivation in

patients with esophageal carcinoma. Diagnostic Pathology 2013, 8:55

2. Teng X-Y, Liu G-Q, Diao X-L, Wu Z-Y, Li L, Zhang W, Zhang X, Su Q*. CAG repeats in the

androgen receptor gene are shorter in patients with pulmonary, esophageal or bladder carcinoma

and longer in women with uterine leiomyoma. Oncol Rep 2010; 23(3):811-818

3. Tian Y, Luo A, Cai Y, Su Q, Ding F, Chen H, Liu Z. MICRORNA-10B promotes human esophageal

cancer cell migration and invasion through KLF4. J Biol Chem 2010; 285(11):7986–7994

4. Li L, Shi YH, Guo ZJ, Qiu T, Guo L, Yang HY, Zhang X, Zhao XM, Su Q*. Prognosis assessment of

extranodal follicular dendritic cell sarcomas, a study of nine cases and a review on 97 cases from

literatures. World J Gastroenterol 2010; 16(20):2504-2519

2

5. Gong L, Li YH, Su Q*, Chu X, Zhang W . Clonality of nodular lesions in liver cirrhosis and

chromosomal abnormalities in monoclonal nodules of altered hepatocytes. Histopathology 2010;

56(5):589-599

6. Cai Y, Gong L, Teng X, Zhang H, Wang C, Wei G, Guo L, Liu Z, Zhang W, Pan Q, Su Q*. Clonality

and allelotype analyses of focal nodular hyperplasia compared with hepatocellular adenoma and

carcinoma. World J Gastroenterol 2009; 15(37):4695-4708

7. Gong L, Zhang W, Su Q. Clonal status of fibrous dysplasia. Pathology 2008; 40(4):392-395

8. Zhu S-J, Li Y-H, W ang Q-T, Guo Y, Cui Y, Su Q, Hacker HJ, Schröder CH, Feng Y-M, Zhang W .

Circulating hepatitis B virus RNA in newborns from carrier mothers. Intervirology 2007; 50:209-213

9. Cai Y-R, Diao X-L, W ang S-F, Zhang W, Zhang H-T, Su Q*. Demonstration of a common clonal

origin in different tumor nodules from some multiple uterine leiomyomas by X-chromosomal

inactivation patterns. Int J Oncol 2007; 31(6):1379-1389

10. Gong L, Su Q*, Zhang W, Li A-N, Zhu S-J, Feng Y-M. Hepatocelluar adenoma, a case report with

clonality analysis. World J Gastroenterol 2006; 12(13):2126-2130

11. Li G, Su Q*, Liu G-Q, Gong L, Zhang W, Wang S-F, Zhu S-J, Zhang H-L, Feng Y-M. Skewed

X-chromosome inactivation of blood cells is associated with early development of lung cancer in

females. Oncol Rep 2006; 16(4):859-864

12. Yang L, Zhang H-T, Zhang X, Sun Y-T, Su Q*. Synchronous occurrence of carcinoid, signet-ring

cell carcinoma and heterotopic pancreatic tissue in stomach, case report and review of literatures.

World J Gastroenterol 2006; 12(44):7216-7220

13. Su Q*, Bannasch P. Relevance of hepatic preneoplasia for human hepatocarcinogenesis. Toxicol

Pathol 2003; 31(1):126-133

14. Su Q*, Fu Y, Liu YF, Zhang W, Liu J, Wang CM. Laminin induces the expression of cytokeratin 19 in

hepatocellular carcinoma cells growing in culture. World J Gastroenterol 2003; 9(5):921-929

15. Su Q*, Wang SF, Chang TE, Breitkreutz R, Hennig H, Takegoshi K, Edler L, Schrö der CH.

Circulating hepatitis B virus nucleic acids in chronic infection: representation of differently

polyadenylated viral transcripts during progression to nonreplicative stages. Clin Cancer Res 2001;

7(7):2005-2015

16. Su Q*, Schröder CH, Otto G, Bannasch P. Overexpression of p53 protein is independent of

hepatitis B virus X protein expression and is associated with neoplastic progression in

hepatocellular carcinomas rather than hepatic preneoplasia. Mutation Res 2000; 462:365-380

17. Su Q*, Schröder CH, Hofmann WJ, Otto G, Pichlmayr R, Bannasch P. Expression of hepatitis B

virus (HBV) X protein in HBV-infected human livers and hepatocellular carcinomas. Hepatology

1998; 27(4):1109-1120

18. Su Q*, Zerban H, Otto G, Bannasch P. Cytokeratin expression is reduced in glycogenotic clear

hepatocytes but increased in ground glass cells in chronic human and woodchuck hepadnaviral

infection. Hepatology 1998; 28(2):347-359

19. Su Q*, Benner A, Hofmann W, Otto G, Pichlmayr R, Bannasch P. Human hepatic preneoplasia:

phenotypes and proliferation kinetics of foci and nodules of altered hepatocytes and their

relationship to liver cell dysplasia. Virchows Arch 1997; 431(6):391-406

20. Su Q*, Liu YF, Wei ZQ. Abnormal cytokeratin expression in experimental liver injury caused by CCl4

administration in rats. Cell Vision 1996; 3(4):297-305

21. Su Q*, Zhang JF, Liu YF, Yang SJ, Zhang SX. Expression of N-ras and c-myc oncogenes in

hepatocellular carcinoma: an in situ hybridization and immunohistochemical study. Cell Vision 1995;

2(5):407-412

22. Su Q*, Liu YF, Zhang JF, Zhang SX, Li DF, Yang JJ. Expression of insulin-like growth factor II in

hepatitis B, cirrhosis and hepatocellular carcinoma, its relationship with hepatitis B virus antigen

expression. Hepatology 1994; 19(4):788-799

Selected certifications:

Board-Certified Anatomical Pathologist in China, 1992;

Certificate for completion of Good Clinical Practice (GCP) training, 2011

English: fluent for oral communication, excellent in reading and writing.

3

Contact this candidate